200670.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong liquidity position, with a current ratio of 8.7, indicating a high ability to meet short-term obligations. It also has a free cash flow of 43,712,898,420 KRW, which supports operational flexibility and potential reinvestment. The company's capital structure is largely equity-driven, with total equity of 299,588,034,330 KRW and minimal long-term debt of 1,361,083,460 KRW, resulting in a debt-to-equity ratio of 0.0.
Profitability metrics are robust, with a return on equity (ROE) of 17.29% and a return on assets (ROA) of 16%. These figures exceed typical industry benchmarks for pharmaceutical firms, suggesting efficient use of equity and assets to generate profit. The company's operating income of 43,436,560,730 KRW and net income of 51,785,617,220 KRW further underscore its strong financial performance.
The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment or geographic detail limits the ability to assess exposure to regional or product-specific risks.
Outlook data indicates a positive trajectory for the company, with analysts providing a mean price target of 65,000 KRW and a median of 62,000 KRW. The mean recommendation of 1.33 suggests a generally favorable view from analysts, with two strong-buy ratings and one buy rating. However, the absence of specific revenue growth projections or segment-level outlooks limits the depth of forward-looking analysis.
Risk factors are minimal, with low liquidity and dilution risk identified. No immediate filing-based flags were detected, and the company's capital structure remains stable with no near-term dilution pressures. The low dilution risk is further supported by the absence of recent equity issuances or shelf registration activity.
Recent events include the publication of the latest financial data, which provides a comprehensive view of the company's performance. No material regulatory or legal events were disclosed in the available data, and the company appears to be operating without significant near-term disruptions.
- The company has a strong liquidity position with a current ratio of 8.7 and a free cash flow of 43.7 billion KRW.
- Profitability is robust, with ROE of 17.29% and ROA of 16%, outperforming typical industry benchmarks.
- The company's capital structure is equity-driven, with minimal long-term debt and a debt-to-equity ratio of 0.0.
- Analysts have a generally favorable outlook, with a mean price target of 65,000 KRW and a mean recommendation of 1.33.
- The company faces low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 4 062,00 |
| Revenue | —no estimate | —no estimate | 199,6B KRW |
| Operating income | —no estimate | —no estimate | 49,6B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 200670.KQ Market data — financials · 2026-05-26
- Humedix Co Ltd Market data — analyst estimates · 2026-05-26